Fibrocell Science Inc (FCSC) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Maria Brooks

Investors sentiment decreased to 0.47 in Q4 2016. Its down 0.03, from 0.5 in 2016Q3. It worsened, as 8 investors sold Fibrocell Science Inc shares while 9 reduced holdings. 2 funds opened positions while 6 raised stakes. 23.97 million shares or 3.70% less from 24.89 million shares in 2016Q3 were reported.
Blackrock Invest Management Ltd Com stated it has 0% in Fibrocell Science Inc (NASDAQ:FCSC). Kcg reported 0% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). Staley Capital Advisers reported 98,500 shares. Renaissance Tech Limited Liability Corporation, New York-based fund reported 194,000 shares. California Pub Employees Retirement Sys accumulated 109,000 shares. Morgan Stanley, New York-based fund reported 25,281 shares. 109,558 are owned by Goldman Sachs Grp. Blackrock Fund Advsr stated it has 62,925 shares or 0% of all its holdings. Franklin Street Nc holds 50,000 shares or 0.01% of its portfolio. Blackrock reported 4,586 shares. Blackrock Institutional Trust Na holds 136,333 shares. Northern Trust invested in 39,087 shares or 0% of the stock. Msd Prns Limited Partnership accumulated 0.07% or 2.08 million shares. Third Security Ltd Liability Corporation, Virginia-based fund reported 16.62M shares. Cambridge Inv Research Advsrs has invested 0% in Fibrocell Science Inc (NASDAQ:FCSC).

The stock of Fibrocell Science Inc (NASDAQ:FCSC) is a huge mover today! The stock increased 5.96% or $0.19 on September 15, reaching $3.38. About 114,100 shares traded or 61.32% up from the average. Fibrocell Science Inc (NASDAQ:FCSC) has declined 57.80% since September 17, 2016 and is downtrending. It has underperformed by 74.50% the S&P500.
The move comes after 7 months positive chart setup for the $49.74M company. It was reported on Sep, 17 by We have $3.58 PT which if reached, will make NASDAQ:FCSC worth $2.98 million more.

Analysts expect Fibrocell Science Inc (NASDAQ:FCSC) to report $-0.41 EPS on November, 2.They anticipate $0.05 EPS change or 13.89 % from last quarter’s $-0.36 EPS. After having $-0.31 EPS previously, Fibrocell Science Inc’s analysts see 32.26 % EPS growth.

Fibrocell Science Inc (NASDAQ:FCSC) Ratings Coverage

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 7 analyst reports since September 28, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, September 28 by Wedbush. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 9. The rating was initiated by Roth Capital on Tuesday, December 22 with “Buy”. As per Tuesday, December 22, the company rating was initiated by TH Capital. H.C. Wainwright maintained the stock with “Buy” rating in Friday, June 9 report.

More notable recent Fibrocell Science Inc (NASDAQ:FCSC) news were published by: which released: “Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational …” on May 10, 2017, also with their article: “Fibrocell Announces One-for-Three Reverse Stock Split” published on March 10, 2017, published: “Fibrocell Announces Leadership Changes” on December 19, 2016. More interesting news about Fibrocell Science Inc (NASDAQ:FCSC) were released by: and their article: “Fibrocell Reports 2016 Financial Results and Recent Operational Highlights” published on March 09, 2017 as well as‘s news article titled: “Fibrocell Science’s (FCSC) CEO John Maslowski on Q2 2017 Results – Earnings …” with publication date: August 11, 2017.

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has market cap of $49.74 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.